178 related articles for article (PubMed ID: 26493999)
1. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Park SJ; Kim SM; Moon JH; Kim JH; Shin JS; Hong SW; Shin YJ; Lee DH; Lee EY; Hwang IY; Kim JE; Kim KP; Hong YS; Lee WK; Choi EK; Lee JS; Jin DH; Kim TW
Tumour Biol; 2016 Apr; 37(4):4323-30. PubMed ID: 26493999
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Chun SG; Zhou W; Yee NS
Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Arnold NB; Arkus N; Gunn J; Korc M
Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
[TBL] [Abstract][Full Text] [Related]
4. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.
Banno E; Togashi Y; de Velasco MA; Mizukami T; Nakamura Y; Terashima M; Sakai K; Fujita Y; Kamata K; Kitano M; Kudo M; Nishio K
Int J Oncol; 2017 Jun; 50(6):2049-2058. PubMed ID: 28440469
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Wu PF; Gao WW; Sun CL; Ma T; Hao JQ
Chin Med J (Engl); 2020 Jun; 133(11):1304-1311. PubMed ID: 32452893
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
Xu XD; Yang L; Zheng LY; Pan YY; Cao ZF; Zhang ZQ; Zhou QS; Yang B; Cao C
BMC Cancer; 2014 May; 14():373. PubMed ID: 24886166
[TBL] [Abstract][Full Text] [Related]
8. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Ahmed AA; Neidle S
Molecules; 2020 Nov; 25(22):. PubMed ID: 33227941
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
11. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Assenat E; Mineur L; Mollevi C; Lopez-Crapez E; Lombard-Bohas C; Samalin E; Portales F; Walter T; de Forges H; Dupuy M; Boissière-Michot F; Ho-Pun-Cheung A; Ychou M; Mazard T
Int J Cancer; 2021 Feb; 148(3):682-691. PubMed ID: 33405269
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.
Zheng L; Fu Y; Zhuang L; Gai R; Ma J; Lou J; Zhu H; He Q; Yang B
Int J Cancer; 2014 Oct; 135(7):1721-32. PubMed ID: 24615207
[TBL] [Abstract][Full Text] [Related]
13. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
[TBL] [Abstract][Full Text] [Related]
14. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
[TBL] [Abstract][Full Text] [Related]
15. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Lee HS; Park SB; Kim SA; Kwon SK; Cha H; Lee DY; Ro S; Cho JM; Song SY
Sci Rep; 2017 Jan; 7():41615. PubMed ID: 28134290
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
Semrad T; Barzi A; Lenz HJ; Hutchins IM; Kim EJ; Gong IY; Tanaka M; Beckett L; Holland W; Burich RA; Snyder-Solis L; Mack P; Lara PN
Int J Clin Oncol; 2015 Jun; 20(3):518-24. PubMed ID: 25091263
[TBL] [Abstract][Full Text] [Related]
17. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K; Hablesreiter R; Inoue Y; Yoshida K; Briest F; Christen F; Kakiuchi N; Yoshizato T; Shiozawa Y; Shiraishi Y; Striefler JK; Bischoff S; Lohneis P; Putter H; Blau O; Keilholz U; Bullinger L; Pelzer U; Hummel M; Riess H; Ogawa S; Sinn M; Damm F
EBioMedicine; 2021 Apr; 66():103327. PubMed ID: 33862582
[TBL] [Abstract][Full Text] [Related]
18. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Samulitis BK; Pond KW; Pond E; Cress AE; Patel H; Wisner L; Patel C; Dorr RT; Landowski TH
Cancer Biol Ther; 2015; 16(1):43-51. PubMed ID: 25485960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]